Tevard Biosciences
@TevardB
Followers
231
Following
163
Media
45
Statuses
101
This month and every month, we stand with the epilepsy community. Founders Daniel Fischer & Warren Lammert, parents of children with Dravet syndrome, are committed to develop therapies that address root causes & bring hope to families. #EpilepsyAwarenessMonth #EndEpilepsy
0
0
1
Excited our CSO, Elisabeth Gardiner, is featured in The Medicine Maker on tRNA therapeutics that restore protein in diseases like #DMD and #DCM. Read more: https://t.co/u8uGSMcYSa
#Biotech #tRNAtherapy #RareDisease
themedicinemaker.com
Engineered tRNAs are redefining precision RNA therapeutics, restoring protein function in diseases caused by nonsense mutations, and bridging the gap between RNA and gene editing technologies.
0
0
1
Sustainable rare disease drug development requires innovative, scalable approaches. In Pharma’s Almanac Roundtable, our CSO Elisabeth Gardiner, PhD, highlights strategies shaping the future. #Biotech #RareDisease #tRNATherapy #PatientDriven #Innovation #Scalable #DrugDevelopment
0
0
2
Tevard CSO Elisabeth Gardiner presented data at FEBS demonstrating the power of Tevard’s suppressor tRNA (suptRNA) platform to rescue full-length, functional proteins in both Duchenne muscular dystrophy (DMD) and dilated cardiomyopathy caused by titin truncations (DCM-TTNtv).
0
0
3
📢 If you’re attending the FEBS Special Meeting in Croatia, don’t miss our CSO Elisabeth Gardiner present exciting new preclinical data showing the transformational potential of our tRNA technology. #GeneticMedicine #tRNA #FEBS
0
0
1
We’re proud to celebrate a new publication in Pharmacology and Therapeutics authored by Prof. Dr. Zoya Ignatova, a member of Tevard’s SAB. This timely review highlights the growing potential of suppressor tRNAs. https://t.co/ewDMmZnYI5
0
0
1
Today, on #WorldDuchenneAwarenessDay, we honor the courage of patients and families facing the daily realities of #DMD. At Tevard, we’re developing tRNA-based gene therapies to address nonsense mutations—aiming to restore dystrophin & support healthy muscle function.
0
0
2
In this podcast, our CEO @Daniel Fischer and @David Wild discuss our unique approach to gene therapy, the technology, and advantages it offers over traditional methods. You’ll also learn more about our lead programs and near-term milestones! https://t.co/R6Ijj3fk5o
insights.citeline.com
Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet...
0
0
1
Don’t forget to register for this impactful event and the discussion of an all-star panel talking about Therapeutic Modalities & Their Relevance to Your Disease. There's still time to register and live stream today's sessions! Register now: https://t.co/bp3WN6Ql5N
0
0
0
This Labor Day, we celebrate the value of teamwork, balance, and the incredible people behind Tevard’s mission—on and off the court. #LaborDay #Teamwork #BiotechCulture
0
0
1
Hear our co-founder and leader Daniel Fischer on how ‘recovering what’s lost in translation’, is central to our approach to gene therapy to restore vital protein production and deliver life-changing therapies for rare diseases caused by nonsense mutations.
Daniel Fischer of @TevardB discusses his journey as the parent of a child with a rare disease, how it led to his co-founding Tevard, and its pursuit of tRNA therapies that may treat a range of diseases with a single medicine. @GlobalGenes #RARECast
https://t.co/eEOY6DNHAP
0
0
0
Register now and don’t miss this session at @GlobalGenes RARE Drug Development Symposium where our CEO Daniel Fischer will join a panel to discuss: 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗠𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 & 𝗧𝗵𝗲𝗶𝗿 𝗥𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 https://t.co/35MqJqQKRC
0
0
1
🚀Congrats to Teerith Pasricha, Victoria Rose, Sophia Zheng, Viggo Blomquist and Steffany Villasenor who are “graduating” from Tevard to pursue PhDs! Thanks for the visit from Tevard co-founder/mentor Harvey Lodish. Excited to see what they’ll do next!
0
0
2
🧬 Happy tRNA Day! We’re pioneering tRNA-based therapies to fix nonsense mutations—restoring full-length protein function and offering hope for patients with rare genetic diseases once thought untreatable. Small molecule, big impact!
1
0
2
In @Nature, our CEO Daniel Fischer--father to a child with a rare disease--shares what drives Tevard: "I know we're working with cell lines and mice, but we're working for kids--and I have one at home." 🧬 Read: https://t.co/VuMH0Baza4
These parents set up biotechnology companies, hoping to cure their children's illnesses https://t.co/Rx4moKIls5
0
0
2
👏 Thanks to @edsilverman and @statnews for highlighting our new CSO, Elisabeth Gardiner. We’re excited to have her join us to advance our tRNA platform to cure rare genetic diseases. 🚶♀️ Learn more about Elisabeth here: https://t.co/XxTMTPKiQk
#tRNA #RareDisease
statnews.com
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
0
0
2
🧬Exciting data from the 2025 RNA Therapeutics conference! Tevard's Julien Oury, PhD shared compelling preclinical results showing suppressor tRNAs restored up to 34% dystrophin & improved muscle function in a DMD model. 🔬 No off-target effects observed.
1
0
6
Today is International #DravetSyndromeAwarenessDay A rare form of epilepsy, Dravet begins in infancy and impacts individuals for life. Our founders have deep personal ties to Dravet; in fact, our company is named for the mission of reversing Dravet (spelled backward is Tevard).
0
0
3
Pleased to present at mRNA Horizons: Investor Summit for Breakthroughs in Medicine on June 24 (10AM–5PM), hosted by @mRNAAlliance with astr partners + @BrownRudnickLLP. Exciting day ahead with top innovators + investors in mRNA! #mRNAHorizons #biotech #lifesciences
0
0
2
Excited to welcome Dr. Elisabeth Gardiner to the team as our new Chief Scientific Officer! Her expertise will be instrumental as we advance our lead program targeting TTN-related dilated cardiomyopathy (data expected soon!) and we expand our pipeline. https://t.co/n3AOsvuDpD
0
0
2